Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M.

Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.

2.

Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.

Bohrer LR, Chen S, Hallstrom TC, Huang H.

Endocrinology. 2010 Nov;151(11):5136-45. doi: 10.1210/en.2010-0436. Epub 2010 Sep 29.

3.

Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.

Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, Chen HW.

Prostate. 2013 Apr;73(5):455-66. doi: 10.1002/pros.22587. Epub 2012 Oct 4.

PMID:
23038103
4.

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.

Daures M, Ngollo M, Judes G, Rifaï K, Kemeny JL, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D.

OMICS. 2016 Feb;20(2):123-5. doi: 10.1089/omi.2015.0113. No abstract available.

PMID:
26871869
5.

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.

Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J, Huang H.

Oncotarget. 2015 Dec 1;6(38):41045-55. doi: 10.18632/oncotarget.5728.

6.

Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.

Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA, Adam RM, Oesterreich S, Di Vizio D, Freeman MR.

Oncogene. 2014 Jun 19;33(25):3235-45. doi: 10.1038/onc.2013.294. Epub 2013 Jul 29.

7.

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.

Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G.

Mol Cancer. 2010 May 17;9:108. doi: 10.1186/1476-4598-9-108.

8.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
9.

EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.

Chinaranagari S, Sharma P, Chaudhary J.

Oncotarget. 2014 Aug 30;5(16):7172-82.

10.

Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.

Nolan KD, Franco OE, Hance MW, Hayward SW, Isaacs JS.

J Biol Chem. 2015 Mar 27;290(13):8271-82. doi: 10.1074/jbc.M115.637496. Epub 2015 Feb 10.

11.

Mutations and deletions of PRC2 in prostate cancer.

Jain P, Di Croce L.

Bioessays. 2016 May;38(5):446-54. doi: 10.1002/bies.201500162. Epub 2016 Mar 22. Review.

PMID:
27000413
12.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

13.

RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.

Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Urano T, Takahashi S, Homma Y, Aburatani H, Inoue S.

Oncotarget. 2015 Feb 10;6(4):2263-76.

14.

EZH2, an epigenetic driver of prostate cancer.

Yang YA, Yu J.

Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30. Review.

15.

Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.

Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON.

Cancer Res. 2012 Sep 15;72(18):4672-81. Epub 2012 Jul 17.

16.

The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.

Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M.

Oncogene. 2007 Jul 5;26(31):4590-5. Epub 2007 Jan 22.

PMID:
17237810
17.

Cooperation between Polycomb and androgen receptor during oncogenic transformation.

Zhao JC, Yu J, Runkle C, Wu L, Hu M, Wu D, Liu JS, Wang Q, Qin ZS, Yu J.

Genome Res. 2012 Feb;22(2):322-31. doi: 10.1101/gr.131508.111. Epub 2011 Dec 16.

18.

Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.

Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M.

PLoS One. 2012;7(10):e47663. doi: 10.1371/journal.pone.0047663. Epub 2012 Oct 15.

19.

Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.

Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J.

BJU Int. 2016 Feb;117(2):351-62. doi: 10.1111/bju.12702. Epub 2015 Apr 21.

20.

Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.

Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM.

Mol Cell. 2013 Jan 10;49(1):80-93. doi: 10.1016/j.molcel.2012.10.008. Epub 2012 Nov 15.

Supplemental Content

Support Center